**1. Introduction**

230 12 Chapters on Nuclear Medicine

Snyder, S. E., et al. (1998). Synthesis of 1-[11C]methylpiperidin-4-yl propionate ([11C]PMP)

Storandt, M., et al. (2009). Cognitive decline and brain volume loss as signatures of cerebral

Sullivan, M. G. (2011). FDA panel on amyloid imaging agent: not yet. *Family Practice News*,

Szardenings, K., et al. (2011). Novel, small molecule [F18]-PET tracers for imaging of tau in

Tamaoka, A., et al. (1994). Biochemical evidence for the long-tail form (A beta 1-42/43) of

Terry, A. V. and Buccafusco, J. J. (2003). The Cholinergic Hypothesis of Age and Alzheimer's

Thal, D. R., et al. (2002). Phases of A-beta deposition in the human brain and its relevance for

Vandenberghe, R., et al. (2010). 18F-Flutemetamol Amyloid Imaging in Alzheimer Disease

Vingerhoets, F. J. G., et al. (1997). Which clinical sign of Parkinson's disease best reflects the

Vitali, P., et al. (2008). Neuroimaging in Dementia. *Semin. Nucl. Med.*, Vol. 28, No. 4, (Oct.

Whone, A. L., et al. (2003). Plasticity of the nigropallidal pathway in Parkinson's disease. *Ann. Neurol.*, Vol. 53, No. 2, (Feb. 2003), pp. 206-213, ISSN 0364-5134. Wimalasena, K. (2011). Vesicular monoamine transporters: Structure-function,

Wong, D. F., et al. (2010). In Vivo Imaging of Amyloid Deposition in Alzheimer Disease

Zhang, W., et al. (2007). 18F-labeled styrylpyridines as PET agents for amyloid plaque imaging. *Nucl. Med. Biol.*, Vol. 34, No. 1, (Jan. 2007), pp. 89-97, ISSN 0047-0740. Zhang, W., et al. (2005a). F-18 polyethyleneglycol stilbenes as PET imaging agents targeting

Zhang, W., et al. (2005b). F-18 stilbenes as PET imaging agents for detecting beta-amyloid

Ziolko, S. K., et al. (2006). Evaluation of voxel-based methods for the statistical analysis of

*Neurol.*, Vol. 66, No. 12, (Dec. 2009), pp. 1476-1481, ISSN 00039942.

No. 8, (Nov. 1998), pp. 751-754, ISSN 0047-0740.

Vol. 41, No. 3, (Feb. 2011), pp. 15, ISSN 0300-7073.

0161-5505.

0028-3878.

827, ISSN 0022-3565.

2010), pp. 319-329, ISSN 0364-5134.

2008), pp. 467-483, ISSN 0001-2998.

(Jun. 2010), pp. 913-920, ISSN 0161-5505.

1, (Oct. 2006), pp. 94-102, ISSN 1053-8119.

pp. 483-519, ISSN 0198-6325.

ISSN 0047-0740.

0022-2623.

291X.

for in vivo measurements of acetylcholinesterase activity,. *Nucl. Med. Biol.*, Vol. 25,

amyloid-β peptide deposition identified with Pittsburgh Compound B. *Arch.* 

human AD brains. *J. Nucl. Med.*, Vol. 52, No. Suppl. 1, (May 2011), pp. 25P, ISSN

amyloid beta protein as a seed molecule in cerebral deposits of Alzheimer's diseae. *Biochem. Biophys. Res. Commun.*, Vol. 205, No. 1, (Nov. 1994), pp. 834-842, ISSN 0006-

Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development *J. Pharm. Expt. Ther.*, Vol. 306, No. 3, (Sep. 2003), pp. 821-

the development of AD. *Neurology*, Vol. 58, No. 12, (Jun. 2002), pp. 1791-1800, ISSN

and Mild Cognitive Impairment A Phase 2 Trial. *Ann. Neurol.*, Vol. 68, No. 3, (Sep.

nigrostriatal lesion? *Ann. Neurol.*, Vol. 41, No. 1, (Jan. 1997), pp. 58-64, ISSN 0364-5134.

pharmacology, and medicinal chemistry. *Med. Res. Rev.*, Vol. 31, No. 4, (Jul. 2011),

Using the Radioligand 18F-AV-45 (Florbetapir F 18). *J. Nucl. Med.*, Vol. 51, No. 6,

Aβ aggregates in the brain. *Nucl. Med. Biol.*, Vol. 32, No. 8, (Nov. 2005), pp. 799-809,

plaques in the brain. *J. Med. Chem.*, Vol. 48, No. 19, (Sep. 2005), pp. 5980-5988, ISSN

PIB PET amyloid imaging studies in Alzheimer's disease. *Neuroimage*, Vol. 33, No.

Therapy with radioiodine (I-131) has been used for patients with well-differentiated thyroid cancer such as papillary and follicular thyroid carcinoma to ablate normal thyroid tissue or to treat metastatic lesions. The improvement of survival rates and decrease of recurrence rates after I-131 therapy has been documented by retrospective studies (Mazzaferri & Jhiang, 1994; Samaan et al., 1992). Even those patients categorized as low risk also had significantly lower recurrence and death rates after they received I-131 (Dietlein et al., 2005). Diagnostic I-123 or I-131 whole body scan (DxWBS) can be performed to detect persistent disease before radioiodine therapy. The post-therapeutic I-131 whole body scan (RxWBS) can be done after administration of therapeutic dose of I-131.
